Kobayashi Pharmaceutical Co., Ltd.
[Kobayashi Pharmaceutical] Q1 2026 Earnings Results | Sales of ¥33.6 billion (+3.2%)
Kobayashi Pharmaceutical's Q1 2026 recorded sales of ¥33.6 billion (YoY +3.2%), with net profit decreasing to approximately ¥1.0 billion. Healthcare and daily用品 are showing signs of recovery, but profits have declined. Continued attention to business performance is warranted.
Key Figures
- Net Sales: ¥33,665 million (YoY +3.2%)
- Net Income Attributable to Owners of Parent: ¥1,036 million (YoY -36.2%)
- Operating Profit: ¥1,350 million (YoY -46.7%)
AI要約
Performance Overview
Kobayashi Pharmaceutical's Q1 2026 recorded net sales of 33,665 million yen (YoY +3.2%), operating profit of 1,350 million yen (down 46.7%), and net income attributable to owners of the parent of 1,036 million yen (down 36.2%). While sales of healthcare and daily用品 are recovering, profit margins have declined. Segmented results show domestic sales of 24,437 million yen (+3.8%) and international sales of 10,558 million yen (+4.6%). Despite steady sales supported by new product launches and resumed advertising, rising costs and increased selling, general and administrative expenses are impacting profit margins.
Outlook and Impact on Shareholders
Going forward, the company plans to continue launching new products and enhancing marketing efforts to expand sales, while cost management remains a key challenge for improving profit margins. Dividend forecasts are maintained, and shareholder returns are expected to continue. The company will monitor geopolitical risks and foreign exchange fluctuations, aiming for stable growth.
Kobayashi Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
